<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="601">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431260</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 54329-101</org_study_id>
    <nct_id>NCT02431260</nct_id>
  </id_info>
  <brief_title>An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of INCB054329 given to patients with advanced malignancies that will be
      conducted in three treatment groups. Each treatment group will have two parts; a dose
      escalation (Part 1) and an expansion (Part 2).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AE)</measure>
    <time_frame>up to 30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of INCB054329 will be determined by the use of validated assays</measure>
    <time_frame>Day 1, 2, 8, 15 and 16 of Cycle 1, up to 24 months (end of treatment )</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Baseline through end of study, up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Baseline through end of study, up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Baseline through end of study, up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Baseline through end of study, up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>INCB054329 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB054329 Monotherapy</intervention_name>
    <description>Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in three treatment groups, with subsequent cohort escalations in the three treatment groups based on protocol-specific criteria</description>
    <arm_group_label>INCB054329 Monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of advanced malignancy:

               -  Treatment Group A (TGA): Part 1:Any advanced solid tumor or lymphoma; Part 2:
                  Histologically confirmed disease in specific tumor types

               -  Treatment Group B (TGB): Leukemia (Part 2 - acute myeloid leukemia [AML] only),
                  myelodysplastic syndrome (MDS), myelodysplastic /myeloproliferative neoplasms
                  (MDS/MPN) and myelofibrosis (MF)

               -  Treatment Group C (TGC): Multiple myeloma

          -  Progressed following at least 1 line of prior therapy and there is no further
             approved therapy available that has been demonstrated to prolong survival (including
             subjects who are intolerant to the approved therapy)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

        Exclusion Criteria:

          -  Inadequate hematopoietic, liver, endocrine or renal function

          -  Receipt of anticancer medications or investigational drugs within the following
             interval before the first administration of study drug:

               -  &lt; 6 weeks for mitomycin-C or nitrosoureas

               -  &lt; 28 days for any investigational agent (for any indication)

               -  &lt; 5 half-lives for all other anticancer medications, or sponsor approval

          -  Prior radiotherapy within 2 weeks prior to first dose of study drug

          -  Untreated brain or central nervous system (CNS) metastases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred Zheng, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Call Center</last_name>
    <phone>1-855-463-3463</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 19, 2016</lastchanged_date>
  <firstreceived_date>April 27, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumor</keyword>
  <keyword>lymphoma</keyword>
  <keyword>BET bromodomain inhibitor</keyword>
  <keyword>BRD</keyword>
  <keyword>Diffuse large B-cell lymphoma (DLBCL)</keyword>
  <keyword>Burkitt's lymphoma</keyword>
  <keyword>c-MYC</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Pancreatic adenocarcinoma</keyword>
  <keyword>castration-resistant prostate cancer</keyword>
  <keyword>breast cancer</keyword>
  <keyword>NUT midline carcinoma</keyword>
  <keyword>leukemia</keyword>
  <keyword>acute myeloid leukemia (AML)</keyword>
  <keyword>atypical chronic myeloid leukemia (aCML)</keyword>
  <keyword>myelodysplastic syndrome (MDS)</keyword>
  <keyword>myeloproliferative neoplasms</keyword>
  <keyword>myelofibrosis (MF)</keyword>
  <keyword>multiple myeloma (MM)</keyword>
  <keyword>CMML</keyword>
  <keyword>MDS/MPN-U</keyword>
  <keyword>RARS-T</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
